Arai Toru, Hirose Masaki, Kagawa Tomoko, Hatsuda Kazuyoshi, Inoue Yoshikazu
Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan.
J Thorac Dis. 2022 Feb;14(2):278-294. doi: 10.21037/jtd-21-1418.
Idiopathic pulmonary fibrosis is a fibrotic disease of unknown aetiology and has a poor prognosis. Some patients experience episodes of rapid deterioration known as acute exacerbations (AEs), which are often fatal. This study aimed to clarify whether serum cytokine levels can predict the outcome of idiopathic pulmonary fibrosis.
This retrospective study included 69 patients with idiopathic pulmonary fibrosis diagnosed according to the 2018 guideline. AE of idiopathic pulmonary fibrosis was diagnosed using the Japanese Respiratory Society criteria. Serum levels of 27 cytokines were measured using the Bio-Plex method. Cytokine production was estimated per lung volume using the serum cytokine level/percent predicted forced vital capacity (%FVC) value. The ability of the serum cytokine level and serum cytokine level/%FVC value to predict the prognosis and AE was examined in a univariate Cox proportional hazards regression model; significant factors were subjected to multivariate analysis with adjustment for significant clinical parameters, including the modified Medical Research Council score.
The study included 57 men and 12 women (median age, 67 years). The modified Medical Research Council score was ≤1 in 47 patients and ≥2 in 22. None of the serum cytokine levels measured could predict survival or AE; however, the serum platelet-derived growth factor/%FVC and interleukin-9/%FVC values were significant prognostic factors and the serum platelet-derived growth factor/%FVC and interleukin-13/%FVC values were significant predictors of AE. Serum platelet-derived growth factor/%FVC alone was a significant predictor of the prognosis and AE after adjustment for clinical parameters.
The prognosis of idiopathic pulmonary fibrosis and AEs of the disease could be predicted by the serum platelet-derived growth factor/%FVC value.
特发性肺纤维化是一种病因不明的纤维化疾病,预后较差。一些患者会经历称为急性加重(AE)的快速恶化期,往往是致命的。本研究旨在阐明血清细胞因子水平是否能预测特发性肺纤维化的预后。
这项回顾性研究纳入了69例根据2018年指南诊断为特发性肺纤维化的患者。特发性肺纤维化的急性加重根据日本呼吸学会标准进行诊断。使用Bio-Plex方法测量27种细胞因子的血清水平。使用血清细胞因子水平/预计用力肺活量百分比(%FVC)值按每肺容积估算细胞因子产生情况。在单变量Cox比例风险回归模型中检验血清细胞因子水平和血清细胞因子水平/%FVC值预测预后和急性加重的能力;对包括改良医学研究委员会评分在内的重要临床参数进行调整后,对显著因素进行多变量分析。
该研究包括57名男性和12名女性(中位年龄67岁)。47例患者的改良医学研究委员会评分≤1,22例患者≥2。所测量的血清细胞因子水平均不能预测生存或急性加重;然而,血清血小板衍生生长因子/%FVC和白细胞介素-9/%FVC值是显著的预后因素,血清血小板衍生生长因子/%FVC和白细胞介素-13/%FVC值是急性加重的显著预测指标。在调整临床参数后,仅血清血小板衍生生长因子/%FVC是预后和急性加重的显著预测指标。
血清血小板衍生生长因子/%FVC值可预测特发性肺纤维化的预后及其急性加重情况。